07:40 AM EDT, 03/27/2026 (MT Newswires) -- Satellos Bioscience ( MSLE ) said Friday that fiscal 2025 net loss widened on higher research expenses.

The company, which is trialling its lead candidate SAT-3247, an oral, small-molecule tablet designed to restore muscle regeneration in Duchenne and potentially other muscle diseases, said net loss widened to US$24.9 million, or US$1.70 per share, from a net loss of US$20.6 million, or US$2.16 per share, for the year ended Dec. 31, 2024. The increase was primarily a result of higher research and development (R&D) expenses for clinical activities associated with SAT-3247.

Satellos had cash of US$27.7 million as of Dec. 31, 2025, compared with US$48.5 million on Dec. 31, 2024. The decrease reflects cash used to fund clinical trial costs and operating activities. The company raised US$57.2 million in February. The cash runway is expected to extend through 2027, a statement said.